Plain-English translation of NCT06708780 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Type 1 Diabetes Mellitus research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
Type 1 diabetes happens when the immune system mistakenly attacks the cells in your pancreas that make insulin. This trial is testing autologous Tregs — special immune cells from your own body that have been grown in a lab and given back to you — to see if they can help stop this attack and preserve your remaining insulin production. Researchers believe this treatment, combined with your regular diabetes care, might slow or even help reverse some of the damage.
In type 1 diabetes, the body's natural immune control breaks down, and people with this condition don't have enough of a specific type of immune cell (called Tregs) that normally prevents this attack. This trial exists to test whether restoring these protective cells by transplanting your own back into your body is both safe and effective.
You likely qualify if…
You likely don't qualify if…
If you join the treatment group, doctors will collect some of your own immune cells, grow and prepare them in a laboratory, and then transplant them back into your body — while you continue taking your regular diabetes medications. The control group will continue standard diabetes care only. You'll likely have multiple visits for cell collection, the transplant procedure, and follow-up appointments to monitor your health and see how the treatment is working.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
China